Omnicell (OMCL) risk factors, FY2024 10-K

Other

1. 01Unfavorable economic and market conditions and a decreased demand in the capital equipment market could adversely affect our business, operating results, cash flow, or financial condition
2. 02We may fail to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner, or our new or enhanced solutions may not achieve market acceptance
3. 03Failure to generate new sales and any reduction in the demand for or adoption of our medication management solutions, medication packaging systems, or related services would reduce our revenues
4. 04Delays in installations of our medication management solutions, including our central pharmacy automation solutions, could harm our competitive position, operating results, and financial condition
5. 05The transition to selling more SaaS and Expert Services, which include a software as a service or solution as a service subscription, presents a number of risks
6. 06If errors occur during the provision of certain of our SaaS and Expert Services, or if we fail to maintain expected service levels, we may be liable to our customers or third parties which may result in a decline in our SaaS and Expert Services offerings revenue
7. 07We may not be able to retain our SaaS and Expert Services customers
8. 08If we are unable to maintain our relationships with group purchasing organizations (“GPOs”) or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations
9. 09If we are unable to meet the demands of, or maintain our relationships with, our institutional and retail pharmacy customers, our revenue from sales of medication packages, other consumables, or our SaaS and Expert Services may decline
10. 10as a result of climate change, will adversely affect our ability to ship our consumable medication packages globally and would reduce our revenues
11. 11Our inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers could have a material adverse effect on our business
12. 12We operate in highly competitive markets, and we may be unable to compete successfully
13. 13We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position
14. 14We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business
15. 15Additionally, data and digital services regulation continues to expand, particularly with respect to AI and automated decision making, which may further impact our business and regulatory compliance strategies
16. 16Significant disruptions in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, could adversely impact our business
17. 17We may fail to realize the potential benefits of acquired businesses, which could negatively affect our business, operating results, cash flow, or financial condition
18. 18If goodwill or other intangible assets that we recorded in connection with our prior acquisitions become impaired, we could be required to take significant charges against earnings
19. 19The healthcare industry is subject to legislative and regulatory changes, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services
20. 20Government regulation of the healthcare industry could reduce demand for our products or services, or substantially increase the cost to produce our products or deliver our services
21. 21Changes to the 340B Program could negatively impact our 340B Program-related services
22. 22We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations
23. 23Our international operations may subject us to additional risks that can adversely affect our business, operating results, cash flow, or financial condition
24. 24If we are unable to anticipate and address these risks properly our business, operating results, cash flow, or financial condition could be harmed
25. 25Covenants in our Second A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and operating results could be adversely affected
26. 26Climate change, legal, regulatory or market measures to address climate change and a focus on environmental, social and corporate governance (“ESG”) matters by various stakeholders may negatively affect our business and operating results
27. 27Furthermore, regulators’, customers’, investors’, and employees’ expectations for ESG matters have been rapidly evolving. The heightened stakeholder focus on these issues requires continuous monitoring of various and evolving standards and the associated reporting requirements
28. 28Catastrophic events may disrupt our business and harm our operating results
29. 29Our success is dependent on our ability to recruit and retain skilled and motivated personnel
30. 30Our failure to protect our intellectual property rights could negatively affect our ability to compete
31. 31We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis
32. 32Our U.S. government lease agreements are subject to annual budget funding cycles and mandated changes, which may affect our ability to recognize revenues and sell receivables based on such leases
33. 33If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer
34. 34Intellectual property claims against us could harm our competitive position, operating results, and financial condition
35. 35Product liability claims against us could harm our competitive position, operating results, and financial condition
36. 36We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products
37. 37Investment in new business strategies, initiatives, products or solutions could disrupt ongoing business and present risks not originally contemplated

Risks Related to Ownership of Our Common Stock

1. 38The market price of our common stock may continue to be highly volatile
2. 39Our quarterly and annual operating results may fluctuate, which makes our future operating results difficult to predict, and may cause our stock price to decline
3. 40If financial or industry analysts have difficulty understanding the changes to our business model, or we fail to meet (or significantly exceed) our publicly announced financial guidance, our stock price and trading volume could decline
4. 41Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, operating results, cash flow, or financial condition
5. 42Certain provisions in our charter documents and under Delaware law may discourage, delay, or prevent an acquisition of us and limit our stockholders’ ability to obtain a favorable judicial forum for certain disputes
6. 43Conversion of the 2029 Notes and the 2025 Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock
7. 44The conditional conversion feature of the 2029 Notes or the 2025 Notes, if triggered, may adversely affect our financial condition and operating results
8. 45The convertible note hedge and warrant transactions may affect the value of our common stock
9. 46Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business, operating results, cash flow, or financial condition
10. 47Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline